RESVINET
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23 >
      • RSVVW'23 Home
      • Registration Fees
      • Visa
      • Accommodation
      • Abstract Submission
      • Young Researchers' Tournament
      • Poster Presentation
      • Accreditation
      • Speakers' Information
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network
  • Home
  • About RSV
    • professionals
    • Publications
  • about us
    • The foundation
    • ReSViNET Team
    • contact us >
      • Support us >
        • Webshop
        • Donate
  • Conference
    • RSVVW'23 >
      • RSVVW'23 Home
      • Registration Fees
      • Visa
      • Accommodation
      • Abstract Submission
      • Young Researchers' Tournament
      • Poster Presentation
      • Accreditation
      • Speakers' Information
    • Previous conferences >
      • RSVVW'21
      • RSVVW'19
      • 4th Meeting 2017
      • 3rd Meeting 2017
      • 2nd Expert Meeting
      • 1st Expert Meeting
  • Webinar Series
  • patient network
    • Activities >
      • Webinars
    • RSV Awareness Week
    • Patient Advisory Board
    • Promise
    • RSV reading material
    • contact patient network

Publications

RSV/NS2/1313/I1314L vaccine in RSV-seronegative children is safe and immunogenic

10/11/2019

0 Comments

 
Ruth A. Karron, Cindy Luongo, Jocelyn San Mateo, Kimberli Wanionek, Peter L. Collins, Ursula J. Buchholz, and the RSVPed Team

The RSV/NS2/1313/I1314L is an intranasal vaccine that contains two attenuating elements in the RSV strain: deletion of the NS2 gene and deletion of the codon 1313. The deletions are stabilized with the substitution of isoleucine at codon 1314. This vaccine induced an immunogenic response in nonhuman primates. A phase 1 double-blind, randomized, placebo-controlled trial was conducted at the Center for Immunization Research (CIR) between 2013 and 2018 in RSV-seronegative and RSV-seropositive children aged 12-59 months. RSV-seronegative children received a single dose of 10 5 or 10 6 PFU and RSV-seropositive children received a single dose of 10 6 PFU. The authors demonstrated that none of the RSV-seropositive children had a ≥4-fold rise in RSV F serum IgG titer. By contrast, 53% of RSV-seronegative children who received 10 5 PFU, developed RSV neutralizing antibodies and F
IgG responses. In RSV-seronegative children receiving 10 6 PFU, even 80% developed RSV neutralizing antibodies and a similar rise in RSV-F IgG antibodies. This indicates that the RSV vaccine is a proper and genetically stable candidate in RSV-seronegative children, which deserves further clinical evaluation in seronegative children. 

This review was written by Safia Laqqa under the supervision of Louis Bont
Download | Paper of the month November 2019
0 Comments

    CATEGORIES

    All
    ReSViNET Publications


    ARCHIVES

    January 2023
    April 2022
    February 2022
    September 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    March 2020
    January 2020
    December 2019
    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    December 2017
    May 2017
    March 2017
    February 2017
    September 2016
    June 2016
    March 2016
    November 2015
    October 2015
    September 2015
    June 2015
    May 2015
    April 2015
    March 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014


    RSS Feed

Note: All information on ReSViNET is for educational purposes only. For specific medical advice, diagnoses, and treatment, consult your doctor.

© 2021 ReSViNET Foundation. All rights reserved.
About us
Disclosure
Contact